Brief news reports on Tuberculosis

WGNV newsletter: Latest updates on TB vaccines

The Stop TB Partnership Working Group on New TB Vaccines (WGNV) released a newsletter with the latest updates related to TB vaccines.

Read More →

What will it take to end TB?

A story tells how the endTB project has improved TB care through a series of scientific studies while pushing the boundaries of what’s thought possible: in clinical trials, in epidemiology, and in the thinking about where you can do the science required to deliver world-class health care where it’s needed most.

Read More →

TB cases rise in England

Figures published by the UK Health Security Agency (UKHSA) in its TB annual report, show that tuberculosis cases in England in 2022 were stable compared to 2021 (4,380 in 2022 compared to 4,411 in 2021).

Read More →

ACTG announces launch of clinical trial evaluating drug-drug interaction in shortened TB regimen among people living with HIV

LOS ANGELES, Feb. 14, 2024 -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 (Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis). A5406 is a phase 2, open-label pharmacokinetic study investigating the effect that the anti-tuberculosis (TB) medication rifapentine has on levels of the HIV medication dolutegravir in the blood of participants who have HIV-associated TB and whether this combination can be safely and effectively used together.

Read More →

TB advocacy resource: A Different Kind of Gap

ACTON releases an advocacy tool exploring what funding gaps in the Global Fund’s Grant Cycle 7 mean for the fight against TB and what happens if they are not filled.

Read More →

Upending the dogma of TB latency: Will it offer new clues for vaccine research?

There are many reasons why HIV is such a perplexing virus to combat. One of them is that there are incredibly few people — only a few, if that, of the nearly 86 million people to acquire HIV to date — who have naturally cleared the virus after becoming infected. Once an HIV infection occurs, it almost always persists in the body for a lifetime.

Read More →

WHO Rapid Communication: TB preventive treatment

The World Health Organization announces forthcoming updates on TB preventive treatment.

Read More →

Multimodal AI model may guide personalized treatments for TB

A team of University of Michigan researchers, led by Sriram Chandrasekaran, Associate Professor, Biomedical Engineering, and postdoctoral fellow Awanti Sambarey developed a multimodal AI model to predict treatment outcomes of tuberculosis (TB) patients. Their analysis of real-world worldwide patient data may lead to personalization of TB treatment. 

Read More →

WHO public consultation for Target Product Profiles for TB screening tests

The World Health Organization (WHO) is in the process of updating high-priority Target Product Profiles (TPPs) for TB screening tests.

Read More →

Research links prison time with increase of TB

Tuberculosis, the main cause of death due to a single pathogen globally, causes more than 1.5 million deaths each year. New research from the University of Cincinnati finds that being in prison or being a former prisoner is responsible for high rates of multidrug-resistant (MDR) TB.

Read More →

Page 1 of 874 · Total posts: 10

1 2 Last→